Webinar March 31, 2017

Key Takeaways from FDA’s Draft Guidance on Communications Consistent with Labeling and Memorandum on Off-Label Communications

Event Detail
March 31, 2017

Julie Tibbets was the featured speaker for this webinar program hosted by Q1 Productions. In January 2017, the FDA released a 63-page memorandum on First Amendment considerations related to off-label communications, as well as a draft guidance entitled “Medical Product Communications That Are Consistent with the FDA-Required Labeling.” This guidance came on the heels of a lively two-day meeting the FDA held in November 2016 to address stakeholder concerns and challenges on communications regarding off-label use of drugs and medical devices. While the draft guidance provides some clarity around permissible on-label communications, uncertainty remains for off-label communications, and the turn of the new Administration may delay the FDA providing any further certainty.

  • Key takeaways and best practices for ensuring on-label marketing claims “consistent” with product labeling
  • Understanding the FDA’s First Amendment
  • Insights from six enforcement letters the FDA issued in December 2016
  • Audience polling on marketing and communication examples based on the FDA’s current recommendations

For more information, click here.

Media Contacts
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222
This website uses cookies to improve functionality and performance. By continuing to browse this site, you are consenting to the use of cookies on this website. For details, see our Privacy Statement